

EXPRESS MAIL CERTIFICATE

Date 6/4/97 Label No. EM016716986
I hereby certify that, on the date indicated above I
deposited this paper or fee with the U.S. Postal Service
and that it was addressed for delivery to the Commissioner
of Patents & Trademarks, Washington, DC 20231 by "Express
Mail Post Office to Addressee" service.

Eileen C. McLoughlin John K. McLaughlin
Name (Print) Signature

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00
OR CREDIT ANY EXCESS IN FUTURE FEES DUE
WITH RESPECT TO THIS APPLICATION TO OUR
DEPOSIT ACCOUNT NO. 04-0100

DARBY & DARBY P.C.

805 Third Avenue
New York, New York 10022
212-527-7700

File No: 7755/OD276

Date: June 4, 1997

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

Sir:

Enclosed please find an application for United States patent as identified below:

Inventor/s (name ALL inventors): Fiona MILLER 1-00 et al

Title: AEROSOL FORMULATIONS

including the items indicated:


1. Specification and 22 claims: 3 indep.; 19 dep.; 0 multiple dep.
2. ☒ Preliminary Amendment

3. [X] Priority is claimed for this application, corresponding application/s having been filed as follows:

Country: Great Britain
Number: GB 9616237.5
Date: 01-August-1996

The priority document ☐ enclosed
☒ will follow.

Respectfully submitted,



Bert J. Lewen
Reg. No. 19,407
Attorney for Applicant(s)

(D&DForms/PTO-1)

EXPRESS MAIL CERTIFICATE

Date 6/4/97 Label No. EM16716986
I hereby certify that, on the date indicated
above I deposited this paper or fee with the
U.S. Postal Service & that it was addressed
for delivery to the Commissioner of Patents
& Trademarks, Washington, DC 20231 by "Express
Mail Post Office to Addressee" service.

Eileen C. McDonough Eileen C. McDonough
Name (Print) Signature

PATENT
File No: 7755/0D276

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Fiona MILLER

Serial No: To be Assigned

Filed: Concurrently Herewith

For: AEROSOL FORMULATIONS

June 4, 1997

PRELIMINARY AMENDMENT

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

Sir:

Please amend the above-identified application, prior to
examination, as follows:

In The Claims:

Please amend Claims 3, 5-9 and 11-17 as follows:

1 3. A formulation as claimed in claim 1 [or claim 2],
2 wherein the medicament is an anti-allergic, a bronchodilator or
3 an anti-inflammatory steroid.

1 5. A formulation, as claimed in [claims 1-3] claim 1,
2 where the medicament is a salt of salbutamol.

1 6. A formulation, as claimed in [claims 1-3] claim 1,
2 where the medicament is a salt of formoterol [(sometimes called
3 eformoterol)].

1 7. A formulation according to [any of claims 1 to 5]
2 claim 1, wherein the propellant is 1,1,1,2-tetrafluoroethane or
3 1,1,1,2,3,3,3-heptafluoro-n-propane.

1 8. A formulation according to [any of claims 1 to 5]
2 claim 1, where the co-solvent level is 10-15%.

1 9. A formulation according to [any of claims 1-5]
2 claim 1, wherein the polar co-solvent is ethanol.

1 11. A canister according to claim [9] 10, fitted into
2 an adaptor with an aperture of 100-300 microns.

1 12. A [product] canister according to [claims 9 and]
2 claim 10 where the medicament is [as per claim 4] ephedrine,
3 adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol,
4 phenylephrine, phenylpropandamine, pirbuterol, reproterol,
5 rimiterol terbutaline, isoetharine, orciprenaline, salbutamol,
6 salmeterol, sodium cromoglycate, fluticasone, beclomethasone or
7 similar molecule and any physiologically acceptable salt, solvate
8 or ester of such compound.

1 13. A [product] canister according to [claims 9-11]
2 claim 10, where the medicament is a salt of salbutamol.

1 14. A [product] canister according to [claims 9-11]
2 claim 10, where the medicament is a salt of formoterol.

1 15. A canister according to [claims 9 and] claim 10,
2 which is actuated by a breath operated device.

1 16. A [product] canister according to claim 15, where
2 the medicament is a salt of salbutamol.

1 17. A [product] canister according to claim 15, where
2 the medicament is a salt of formoterol.

Please add claims 18-22 as follows:

1 18. A formulation as claimed in claim 2, wherein the
2 medicament is an anti-allergic, a bronchodilator or an anti-
3 inflammatory steroid.

1 19. A formulation as claimed in claim 18, where the
2 medicament is ephedrine, adrenaline, fenoterol, formoterol,
3 isoprenaline, metaproterenol, phenylephrine, phenylpropandamine,
4 pirbuterol, reproterol, rimiterol terbutaline, isoetharine,
5 orciprenaline, salbutamol, salmeterol, sodium cromoglycate,
6 fluticasone, beclomethasone or similar molecule and any physio-
7 logically acceptable salt, solvate or ester of such compound.

1 20. A formulation according to claim 2, wherein the
2 propellant is 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-
3 heptafluoro-n-propane.

1 21. A formulation according to claim 2, where the co-
2 solvent level is 10-15%.


1 22. A formulation according to claim 2, wherein the
2 polar co-solvent is ethanol.

REMARKS

Claims 3, 5-9 and 11-17 have been amended and claims
18-22 have been added to eliminate multiple claim dependency.

Entry of this amendment is respectfully requested.

Respectfully submitted,


Bert J. Lewen
Reg. No. 19,407
Attorney for Applicant(s)

DARBY & DARBY P.C.
805 Third Avenue
New York, New York 10022
212-527-7700

On 4/19/77 Label No. EX016716986
I hereby certify that, on the date indicated above I
deposited this paper or fee with the U.S. Postal Service
& that it was addressed for delivery to the Commissioner
of Patents & Trademarks, Washington, DC 20231 by "Express
Mail Post Office to Addressee" service.

-1-

AEROSOL FORMULATIONS

Elmer C. McLaughlin Elmer C. McLaughlin
Name (Print) Signature

This invention relates to pharmaceutical formulations for inhalation aerosols. The Montreal Protocol on ozone depleting gases has made the reformulation of existing pharmaceutical aerosols for inhalation treatment containing chlorofluorohydrocarbon propellants, a matter of urgency for the pharmaceutical industry.

A number of hydrofluorocarbons (HFCs) have been the subject to toxicological testing and two in particular P134a (1,1,1,2-tetrafluoroethane) and P227 (1,1,1,2,3,3,3-heptafluoropropane) have been identified as safe for use in pharmaceutical aerosols.

A number of patent applications have been submitted in this field, the first being EP 372777, which discloses the use of four component mixtures, comprising a medicament, a surfactant, P134a and a co-solvent of higher polarity than the P134a, in the form of a solution or a suspension.

As inhalation aerosols are meant for administration to the lung, it has long been accepted that such formulations should contain as few ingredients as possible, to avoid putting unnecessary materials into the lung.

Historically, despite EP 372777, solution aerosols contained only medicament, propellant or propellant mixtures and, if necessary, co-solvent, usually ethanol, eg US 2868691. The use of a surfactant was normally unnecessary for solution aerosols. However, historically medicinal suspension aerosols have contained a surfactant eg US 3014844, as it was considered that the use of a surfactant was necessary to prevent agglomeration of particles, to prevent adhesion to the sides of the canister, and to aid valve lubrication and prevent valve sticking.

However it was disclosed in EP 616525 that it is possible to prepare medicament suspensions in a hydrofluorocarbon without the need for a surfactant, if a polar co-solvent was added. The normal co-solvent ethanol, has well established

physiological actions and being a pure absorbable liquid eliminates any possibility of residues remaining in the lung. Irritation or possible toxicity from the surfactant, many of which are mixtures of similar compounds, are avoided.

EP 616525 specifically limits the polar co-solvent level to 0.01 to 5% w/w and in particular states (page 3, line 55) that the preferred level is about 0.1% w/w.

According to a first aspect of the present invention there is provided a medicinal aerosol formulation comprising a particulate medicament, a fluorocarbon propellant and 6% to 25% w/w of the total formulation of a polar co-solvent, such formulation being substantially free of surfactant.

According to a second aspect of the present invention there is provided a medicinal aerosol formulation, comprising one or more particulate medicaments, one or more fluorocarbon or hydrocarbon or aliphatic gas propellants and 6% to 25% w/w of a polar co-solvent.

According to a third aspect of the present invention there is provided a canister suitable for delivering a pharmaceutical aerosol formulation, which comprises a container capable of withstanding the vapour pressure of the propellant used, which container is closed with a metering valve and contains a pharmaceutical aerosol formulation which comprises particulate medicament, a propellant consisting all or part of fluorocarbon and 6% to 25% of a polar co-solvent, which is substantially free of surfactant.

It has now been surprisingly found that higher levels of alcohol have beneficial results. Levels of 6% or more of ethanol produce satisfactory suspensions, which do not agglomerate on standing, and on reshaking produce finely dispersed medicament. It is believed that the higher levels of alcohol reduce the degree of deposition on the inside of the can. This is a very desirable feature. In addition, the use of these larger percentages of ethanol enables a much cheaper production process.

Medicinal aerosols can be filled either with one dose of liquid containing all of the ingredients mixed together or by

a two dose process where the first dose contains the medicament and all other ingredients, including co-solvents, surfactants, if any, ancillary compounds eg flavours, if any, and some times some of the propellant followed by a second dose of pure propellant. This two dose fill has major cost advantages in that the volume of mix for a fixed number of cans is significantly smaller enabling the use of smaller mixing vessels. In particular, with the use of the new HFC propellants, which have lower boiling points than the old CFC propellants, the use of a one dose fill may involve the use of cooled pressurised vessels to prevent evaporation of the propellant gas during mixing and filling. With the new formulations with added extra co-solvent a first mix of just medicament suspended in the co-solvent can be used, followed by a second dose of pure propellant. This means that the propellant can be dosed directly from a holding tank into the can without any need to mix and store with the other ingredients. For example a mix weight of 1g of medicament and co-solvent can be followed by 7.5g of propellant. In this way the volume to be mixed is reduced from 8.5g to 1g. All the examples in EP 616525 are of laboratory scale, where the handling problems are much easier, but all the formulations described are such that it would not be practicable to fill in two doses without mixing the propellant, as is the case with the present disclosure.

The description of the filling method given on page 5 lines 2-13 indicates that only a one dose filling method is envisaged.

In all cases of the present invention the medicament consists of a particle size suitable for inhalation into the lung and will thus be less than 100 microns, desirably less than 20 microns and preferably in the range of 1-10 microns, normally with a mean particle size 1-5 microns.

Medicaments which may be administered in aerosol formulations according to the invention include any drug useful in inhalation therapy which may be presented in a form which is substantially completely insoluble in the selected propellant.

Appropriate medicaments may thus be selected from, for example, analgesics, eg codeine, dihydromorphine, ergotamine, fentanyl or morphine; anginal preparations, eg diltiazem; antiallergics, eg cromoglycate, ketotifen or nedocromil; anti-infectives, eg cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines and pentamidine; antihistamines, eg methapyrilene; anti-inflammatories, eg beclomethasone, flunisolide, budesonide, tipredane, triamcinolone acetonide or fluticasone; antitussives, eg noscapine; bronchodilators, eg ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, salbutamol, salmeterol, terbutaline, isoetharine, tolubuterol, orciprenaline; diuretics, eg amiloride; anticholinergics, eg ipratropium, atropine or oxitropium; hormones, eg cortisone, hydrocortisone or prednisolone; xanthines, eg aminophylline, choline theophyllinate, lysine theophyllinate or theophylline; and therapeutic proteins and peptides, eg insulin or glucagon. It will be clear to a person skilled in the art that, where appropriate, the medicaments may be used in the form of salts (eg as alkali metal or amine salts or as acid addition salts) or as esters (eg lower alkyl esters) or as solvates (eg hydrates) to optimise the activity and/or stability of the medicament and/or to minimise the solubility of the medicament in the propellant.

Preferred are those compounds which are also substantially insoluble in the co-solvent. Particularly preferred as medicament is salbutamol either as base or as a salt and especially salbutamol sulphate.

Co-solvents may be selected from polar alcohols and polyols, particularly C₂-C₆ aliphatic alcohols and polyols, such as propylene glycol, and preferably ethanol. Levels of co-solvent will be between 6% and 25% w/w of the total canister content, preferably between 10-15% w/w of canister content.

The propellant may be a hydrofluorocarbon, particularly P134a or P227. Other hydrofluorocarbons or hydrocarbons or aliphatic gases (eg Dimethylether) may be added to modify the

propellant characteristics as required.

The product is preferentially produced by weighing the active medicament and suspending it in the co-solvent. The appropriate amount of suspension is then dosed into the can, followed by a second dose of propellant or propellant mix. However, a one shot fill or any other equivalent method may be employed.

The normal medicinal product on the market has an actuator with spray orifice diameter of about 480 microns. However, with the larger percentages of ethanol envisaged in this invention, it is desirable that the co-solvent evaporates from the particles as rapidly as possible.

This is achieved by reducing the aperture to between 100-300 microns, which for the same dosage or drug, gives more rapid evaporation of the co-solvent. A particularly preferred embodiment of the invention is a combination of a level 10-15% co-solvent (normally ethanol) with a stem aperture of 150-250 microns.

The invention is further described by means of example but not in any limitative sense.

Example

Salbutamol Sulphate	0.03g
Ethanol	0.97g
Tetrafluoroethane (P134a)	7.5g

The salbutamol sulphate previously micronised to give over 90% of particles below 10 microns was weighed out and added to the ethanol. The suspension was mixed until it was smooth and uniform and then filled into the aerosol canister. The metering valve assembly was crimped (preferably vacuum crimped) on the canister and then the P134a was filled through the valve. The valve capacity is such as to deliver 100 micrograms of salbutamol, as salbutamol sulphate per actuation.

A particularly preferred use of such a canister is in a patient breath operated device rather than the normal hand

operated device. Such devices are available commercially such as those under the trade mark "Easi-Breathe".

Claims:

1. A medicinal aerosol formulation comprising a particulate medicament, a fluorocarbon propellant and 6% to 25% w/w of the total formulation of a polar co-solvent, such formulation being substantially free of surfactant.

2. A medicinal aerosol formulation, comprising one or more particulate medicaments, one or more fluorocarbon or hydrocarbon or aliphatic gas propellants and 6% to 25% w/w of a polar co-solvent.

3. A formulation as claimed in claim 1 or claim 2, wherein the medicament is an anti-allergic, a bronchodilator or an anti-inflammatory steroid.

4. A formulation as claimed in claim 3, where the medicament is ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, phenylephrine, phenylpropandamine, pirbuterol, reproterol, rimiterol, terbutaline, isoetharine, orciprenaline, salbutamol, salmeterol, sodium cromoglycate, fluticasone, beclomethasone or similar molecule and any physiologically acceptable salt, solvate or ester of such compound.

5. A formulation, as claimed in claims 1-3, where the medicament is a salt of salbutamol.

6. A formulation, as claimed in claims 1-3, where the medicament is a salt of formoterol (sometimes called eformoterol).

7. A formulation according to any of claims 1 to 5, wherein the propellant is 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n-propane.

8. A formulation according to any of claims 1 to 5,

where the co-solvent level is 10-15%.

9. A formulation according to any of claims 1-5, wherein the polar co-solvent is ethanol.

10. A canister suitable for delivering a pharmaceutical aerosol formulation, which comprises a container capable of withstanding the vapour pressure of the propellant used, which container is closed with a metering valve and contains a pharmaceutical aerosol formulation which comprises particulate medicament, a propellant consisting all or part of fluorocarbon and 6% to 25% of a polar co-solvent, which is substantially free of surfactant.

11. A canister according to claim 9, fitted into an adaptor with an aperture of 100-300 microns.

12. A product according to claims 9 and 10 where the medicament is as per claim 4.

13. A product according to claims 9-11, where the medicament is a salt of salbutamol.

14. A product according to claims 9-11, where the medicament is a salt of formoterol.

15. A canister according to claims 9 and 10, which is actuated by a breath operated device.

16. A product according to claim 15, where the medicament is a salt of salbutamol.

17. A product according to claim 15, where the medicament is a salt of formoterol.

Abstract:

The replacement of chlorofluorohydrocarbon propellants in medical aerosols is of the utmost importance to the pharmaceutical industry. A number of formulations have been investigated.

The present invention provides a medical aerosol formulation comprising a particular medicament, a fluorocarbon propellant and 6 to 25% w/w of the total formulation of a polar co-solvent, such formulation being substantially free of surfactant. Cannisters suitable for delivering such a pharmaceutical formulation are also provided.

**ALL FOREIGN APPLICATIONS, IF ANY, FILED PRIOR
TO THE APPLICATION(S) OF WHICH PRIORITY IS CLAIMED**

COUNTRY APPLICATION NO. DATE OF FILING

POWER OF ATTORNEY:

As a named inventor, I hereby appoint the following attorney(s) and/or agents(s) to prosecute this application and transact all business in the Patent and Trademark office connected therewith. Gordon D Coplein #19,165, William F Dudine, Jr #20,569, Michael J. Sweedler #19,937, S Peter Ludwig #25,351, Paul Fields #20,298, Harold E Wurst #22,183, Joseph B Lerch #26,936, Melvin C Garner #26,272, Ethan Horwitz #27,646, Beverly B. Goodwin #28,417, Adda C Gogoris #29,714, Martin E Goldstein #20,869, Bert J Lewen #19,407, Henry Sternberg #22,408, Robert A. Green #28,301, Peter C. Schechter #31,662, Robert Schaffer #31,194, David R Francescani #25,159, Robert C Sullivan, Jr #30,499, Ira J Levy #35,587, Joseph R Robinson #33,448

all of the firm of DARBY & DARBY P.C., 805 Third Avenue, New York, NY 10022

SEND CORRESPONDENCE TO:

DIRECT TELEPHONE CALLS TO:

DARBY & DARBY P.C.
805 Third Avenue
New York, NY 10022

Bert J. Lewen
212-527-7700

FULL NAME AND RESIDENCE OF INVENTOR 1

LAST NAME **MILLAR** FIRST NAME **Fiona** MIDDLE NAME **Catherine**
WATERFORD 7/1 8/5/98 *IRELAND 7/1 8/5/98*
CITY: ~~Harlow, Essex~~ STATE OR FOREIGN COUNTRY: ~~England~~ COUNTRY OF CITIZENSHIP **Ireland**

POST OFFICE ADDRESS **c/o Norton Healthcare Limited, Gemini House, Flex Meadow**


CITY **Harlow, Essex** STATE OR COUNTRY **England** ZIP CODE

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 1: *X* *[Signature]* DATED: *X* *8/5/98*
8th May 1998

(D&DForms/PTO-21)

REV. 12/87



FILE NO.: 7755/OD276

**DECLARATION
AND POWER OF ATTORNEY
Original Application**

As a below named inventor, I declare that the information given herein is true, that I believe that I am the original, first and sole inventor if only one name is listed at 1 below, or a joint inventor if plural inventors are named below, of the invention entitled:

AEROSOL FORMULATIONS

which is described and claimed in:

☐ the attached specification or ☒ the specification in application
Serial No. 08/999,752
filed June 4, 1997
(for declaration not accompanying appl.)

that I do not know and do not believe that the same was ever known or used in the United States of America before my or our invention thereof or patented or described in any printed publication in any country before my or our invention thereof, or more than one year prior to this application, or in public use or on sale in the United States of America more than one year prior to this application, that the invention has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on an application filed by me or my legal representatives or assigns more than twelve months prior to this application, that I acknowledge my duty to disclose information of which I am aware which is material to patentability in accordance with 37 CFR §1.56. I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above. I hereby claim the priority benefits under 35 U.S.C. 119 of any application(s) for patent or inventor's certificate listed below. All foreign applications for patent or inventor's certificate on this invention filed by me or my legal representatives or assigns prior to the application(s) of which priority is claimed are also identified below.

PRIOR APPLICATION(S), IF ANY, OF WHICH PRIORITY IS CLAIMED

<u>COUNTRY</u>	<u>APPLICATION NO.</u>	<u>DATE OF FILING</u>
Great Britain	GB 9616237.5	01-August-1996